As of November 6, 2026, AEON Biopharma, Inc. is a publicly traded company (NYSE: AEON). The largest holder reporting an active stake on Schedule 13D is Daewoong Co.,Ltd., at 49.99%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Timothy P. Lynch, a 10% owner (13%, reporting on Schedule 13G) (Schedule 13D, January 29, 2026).
Is this your company?
About to sign with, pay or invest in AEON Biopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is AEON Biopharma, Inc. a real, registered company?
- AEON Biopharma, Inc. files with the SEC under CIK 1837607 (its SEC filings).
- Its shares are listed under the ticker AEON on NYSE (SEC company record).
- Incorporated in Delaware; business address in Aliso Viejo, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under AEON Biopharma, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Timothy P. Lynch (filed 2026-08-21).
Who are AEON Biopharma, Inc.'s owners and officers?
AEON Biopharma, Inc.: incorporated in Delaware; business address in Aliso Viejo, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-21).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-21 | Timothy P. Lynch | 13% |
| Schedule 13G, 2026-07-21 | Stonepine Capital Management, LLC | 9.9% |
| Schedule 13D, 2026-01-29 | Daewoong Co.,LTD. ("Dwc") | 49.99% |
| Schedule 13D/A, 2026-01-29 | Daewoong Co.,LTD. ("Dwc") | 0.9% |
| Schedule 13G/A, 2025-10-14 | Alta Partners LLC | 2.1% |
| Schedule 13G/A, 2025-07-09 | Alta Partners LLC | 5.1% |
Questions about who owns AEON Biopharma, Inc.
Who owns AEON Biopharma, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of AEON Biopharma, Inc.: Daewoong Co.,LTD. ("Dwc") (49.99%, Schedule 13D, filed 2026-01-29), Timothy P. Lynch (13%, Schedule 13G, filed 2026-08-21) and Stonepine Capital Management, LLC (9.9%, Schedule 13G, filed 2026-07-21).
Who are the largest shareholders of AEON Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of AEON Biopharma, Inc. on this page are Daewoong Co.,LTD. ("Dwc") (49.99%), Timothy P. Lynch (13%) and Stonepine Capital Management, LLC (9.9%).
When did Daewoong Co.,LTD. ("Dwc") buy into AEON Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Daewoong Co.,LTD. ("Dwc") on this page is the Schedule 13D, filed 2026-01-29, reporting 49.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on AEON Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on AEON Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AEON Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own AEON Biopharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Daewoong Co., Ltd, a 10% owner: 12,009,737 shares (24.1% of shares outstanding), 58,023 held directly and 11,951,714 indirectly (Form 3, 2026-01-29).
- , a 10% owner: 6,500,000 shares (13.0% of shares outstanding) (Form 4, 2026-08-21).
- , the chief executive and president: 3,177,103 shares (6.4% of shares outstanding) (Form 4, 2026-02-19).
- , the chief medical officer: 2,183,436 shares (4.4% of shares outstanding) (Form 4, 2026-03-11).
- , the chief legal officer and cso: 2,183,005 shares (4.4% of shares outstanding) (Form 4, 2026-03-05).
Shares outstanding: 49,882,790 as of 2026-08-06, from the company's latest SEC cover page.
How much has AEON Biopharma, Inc. raised?
Latest IPO step: AEON Biopharma, Inc. filed its final IPO prospectus, ticker AEON (424B4, 2026-07-15).
IPO filings: 424B4, 2026-07-15, S-1/A, 2026-07-09, S-1, 2026-07-08, S-1/A, 2024-07-23; ticker AEON on NYSE American.
Keep reading
More on AEON Biopharma, Inc. and the records around it.
AEON Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Timothy P. Lynch also filed stake reports on 1 other company: Evolus, Inc. (Feb 2026)
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aeon-biopharma